Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00415142 · ClinicalTrials.gov registry record · Phase 3
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 393
- Enrollment target
NCT00415142 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 393 participants.
The verdict
NCT00415142, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 393 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients with major depressive disorder.To evaluate safety and tolerability of 24 weeks of additional treatment in patients completing the initial 8-week treatment period.
Interventions
- DRUG placebo
- DRUG escitalopram
- DRUG saredutant (SR48968)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 393 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00415142
The ClinicalTrials.gov registry entry for NCT00415142 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 393 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00415142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00415142 about?
NCT00415142 is a clinical study titled "An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder". The purpose of the study is to evaluate the efficacy of saredutant in the treatment of Major Depressive Disorder in elderly patients.To evaluate the tolerability, safety and efficacy on disability and quality of life in patients with major depressive disorder.To evaluate safety and tolerability of 2...
What is the current status of trial NCT00415142?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 393 participants. The study started on 2006-12. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00415142?
The interventions under investigation include: placebo (DRUG), escitalopram (DRUG), saredutant (SR48968) (DRUG).
Who is sponsoring clinical trial NCT00415142?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.